DURECT Corporation
2 Results Way
Cupertino
California
95014
United States
Tel: 408-777-1417
Fax: 408-777-3577
Website: http://www.durect.com/
395 articles about DURECT Corporation
-
Biopharma Executive Perspectives on 2022
1/10/2022
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade. -
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
1/6/2022
DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
12/22/2021
- DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales and Innocoll granted exclusive development and commercialization rights to POSIMIR in the United States.
-
BioSpace Movers & Shakers, Dec. 17
12/17/2021
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers. -
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
12/14/2021
DURECT Corporation announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience.
-
DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit
11/29/2021
DURECT Corporation announced it will participate in a workshop at the 5th Annual NASH Summit being held virtually.
-
Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.
11/12/2021
DURECT Corporation announced the presentation of data at the American Association for The Study of Liver Diseases The Liver Meeting® 2021 showcasing an increase of hospitalizations for alcohol-associated hepatitis in the U.S. of approximately 19% or approximately 4.8% per year between 2015 and 2018.
-
DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs
11/2/2021
DURECT Corporation announced financial results for the three months ended September 30, 2021 and provided a corporate update.
-
DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2
10/26/2021
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the market close on Tuesday, November 2, 2021 .
-
DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021
9/23/2021
DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Kristen Kluska, Director, Equity Research Analyst at Cantor Fitzgerald.
-
DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit
9/15/2021
DURECT Corporation announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc.
-
DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference
9/7/2021
DURECT Corporation announced that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H.C. Wainwright, at the H.C. Wainwright 23rd Annual Global Investment Conference.
-
DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs
7/29/2021
DURECT CorporationDURECT Corporation announced financial results for the three months ended June 30, 2021 and provided a corporate update.
-
DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29
7/22/2021
DURECT Corporation announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.
-
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
7/14/2021
DURECT Corporation announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021.
-
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
6/9/2021
DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26 , 2021.
-
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs
5/4/2021
DURECT Corporation announced financial results for the three months ended March 31, 2021 and provided a corporate update.
-
DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4
4/27/2021
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2021 financial results and host a conference call after the market close on Tuesday, May 4, 2021 . Tuesday, May 4 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time
-
BioSpace recently spoke with Norman Sussman, chief medical officer at DURECT, a company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.